BOSTON, June 25, 2024 /PRNewswire/ -- Skyhawk
Therapeutics, Inc., a clinical-stage biotechnology company
developing novel small molecule therapies designed to modulate
critical RNA targets, today announced its expansion into new state
of the art labs in Superlab Suisse, in Basel Switzerland.
"Skyhawk has achieved tremendous scientific advances in our
Basel Switzerland location so
far," said Sergey Paushkin, Chief Scientific Officer of Skyhawk
Therapeutics. "This new space helps us grow our gifted senior
scientific team and capabilities as we work to revolutionize
disease treatment and develop therapies for some of the world's
most intractable diseases."
"This is an exciting time at Skyhawk," said Clint Musil, Chief Executive Officer of Skyhawk
Therapeutics. "With our first program for Huntington's disease progressing in the clinic
and our second program, SKY-1214, on track to enter the clinic,
we've doubled our lab space in Basel to drive a series of promising INDs.
Superlab Suisse is a leading provider of innovative research space
and the largest private lab space in Switzerland, with a mission to provide dynamic
infrastructure for Switzerland's
life sciences sector. Skyhawk is delighted to be part of this
growing biotechnology hub in Basel."
About Skyhawk Therapeutics
Skyhawk Therapeutics is a
clinical-stage biotechnology company focused on the discovery and
development of novel small molecule therapies designed to modulate
critical RNA targets and revolutionize patient treatment for some
of the world's most intractable diseases. Skyhawk's discovery
expertise is rooted in its proprietary drug discovery platform,
which is designed to assess, identify, and test RNA splicing
targets and small molecules across a broad range of therapeutic
areas and disease states. Skyhawk has built collaborations with
BMS, Biogen, Genentech, Merck, Sanofi, Takeda, Vertex, and Ipsen
that leverage Skyhawk's novel platform across disease areas
including neurodegenerative disease, autoimmune disease, and
oncology. For more information visit www.skyhawktx.com.
About the Skyhawk Platform
Skyhawk's platform
integrates four distinct and complementary data sets in rapidly
growing machine learning models, accelerating the development of
RNA targeting small molecule drug candidates across a range of
targets. SKYSTAR®, a target assessment system
integrating data from both public and proprietary bioinformatic,
structural and computational biology data sets to prioritize
high-value RNA targets. SKYLIBRARY™, a unique, custom
built and rapidly expanding library of RNA targeting compounds.
SKYSEQ™, a proprietary multiplex screening system that
simultaneously tests dozens of high-value targets across a range of
RNA structural motifs to identify compounds selective for a
specific disease target. And SKYAI™, our machine
learning toolset that integrates data from SKYSTAR, medicinal
chemistry, animal studies, toxicology data and clinical programs to
drive the next generation of novel RNA splicing modulators.
Skyhawk Company Contact
Maura
McCarthy, SVP Market Development
maura@skyhawktx.com
Investor Contact
AnneMarie Fields, Stern Investor Relations
annemarie.fields@sternir.com
332-213-1956
Logo -
https://mma.prnewswire.com/media/710814/4782462/Skyhawk_Therapeutics_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/skyhawk-therapeutics-expands-into-state-of-the-art-labs-in-its-basel-switzerland-location-302182329.html